[1]JournalofPharmaceuticalSciences,1994,vol.83,#2,p.252-254
Title: Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Journal: Chemical research in toxicology 20170515
Title: Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Journal: PLoS computational biology 20111201
Title: Determination of ebrotidine and its metabolites by micellar electrokinetic capillary chromatography.
Journal: Journal of chromatography. A 20021108
Title: [Prospect of the development of new bactericidal drugs against Helicobacter pylori for eradication therapy].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20020201
Title: Determination of ebrotidine metabolites in overlapping peaks from capillary zone electrophoresis using chemometric methods.
Journal: Electrophoresis 20010101
Title: Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
Journal: European journal of gastroenterology & hepatology 20000301
Title: Agut J, Sánchez JC, Sacristán A, Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors. Arzneimittelforschung. 1997 Apr;47(4A):447-9.
Title: Palop D, Agut J, Márquez M, Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
Title: Konturek SJ, Kwiecien N, Sito E, Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans. Scand J Gastroenterol. 1993 Dec;28(12):1047-50.
Title: Piotrowski J, Yamaki K, Morita M, Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity. Biochem Int. 1992 Mar;26(4):659-67.
